Drug Type Small molecule drug |
Synonyms Acantex, Ceftezole Sodium, Ceftriaxone + [26] |
Target |
Action inhibitors |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (21 Dec 1984), |
RegulationOrphan Drug (European Union) |
Molecular FormulaC36H50N16Na4O21S6 |
InChIKeyHPYJOGROSRTMBB-MAODNAKNSA-N |
CAS Registry104376-79-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00924 | Ceftriaxone Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Arthropathy associated with infection | Australia | 28 Jan 2003 | |
Infection of bone | Australia | 28 Jan 2003 | |
Postoperative infection | Australia | 28 Jan 2003 | |
Skin and skin structure infections | Australia | 28 Jan 2003 | |
Genitourinary tract infection | China | 01 Jan 1998 | |
Lyme Disease | China | 01 Jan 1998 | |
Reproductive Tract Infections | China | 01 Jan 1998 | |
Respiratory Tract Infections | China | 01 Jan 1998 | |
Wound Infection | China | 01 Jan 1998 | |
Biliary tract infection | China | 01 Jan 1991 | |
Bone and joint infections | China | 01 Jan 1991 | |
Gonorrhea | China | 01 Jan 1991 | |
Infectious Diseases | China | 01 Jan 1991 | |
Intraabdominal Infections | China | 01 Jan 1991 | |
Lower Respiratory Tract Infections | China | 01 Jan 1991 | |
Meningitis | China | 01 Jan 1991 | |
Pelvic Infection | China | 01 Jan 1991 | |
Sepsis | China | 01 Jan 1991 | |
Skin structures and soft tissue infections | China | 01 Jan 1991 | |
Urinary Tract Infections | China | 01 Jan 1991 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ileitis | Phase 2 | Canada | 01 Jun 2015 | |
Infection of ear | Clinical | China | 04 Aug 2025 | |
Nasal infection | Clinical | China | 04 Aug 2025 | |
Peritonitis | Clinical | China | 04 Aug 2025 | |
Pharyngitis | Clinical | China | 04 Aug 2025 | |
Pneumonia | Clinical | China | 04 Aug 2025 | |
HIV Infections | Clinical | United States | 31 Aug 2001 | |
Neurosyphilis | Clinical | United States | 31 Aug 2001 |
Literature Manual | Phase 2/3 | 64 | iwdrfnujbv(jdstipntpv) = mhuqivojol itouonhidk (wwixxlufpb ) View more | Non-inferior | 17 Feb 2025 | ||
iwdrfnujbv(jdstipntpv) = odntcebsah itouonhidk (wwixxlufpb ) View more | |||||||
Phase 4 | 42 | (Rocephine®) | wsqbeqyrry(dtjqcesnba) = obpjfxjubc dsosyjbkyl (sfvazkivgc, hprvxkgmoz - kmezycufoq) View more | - | 02 Aug 2024 | ||
(Rocephine® + Azithromycin) | vxbfttzchq = keypdocvgr tvdlvoexnr (xlfbuozncr, caiiubmxyy - frnurispdr) View more | ||||||
Phase 3 | 319 | ouxuyuokxz(elqanijabz) = lyzrbxkayv saocptsnpp (fgyzqnvvhp ) | Positive | 19 Jan 2024 | |||
Placebo | ouxuyuokxz(elqanijabz) = civosvcprq saocptsnpp (fgyzqnvvhp ) | ||||||
NCT04218695 (Pubmed) Manual | Phase 4 | 30 | twlqmrntyg(mqbzppcvbe) = There were no observed statistically significant differences between groups in incidence of infection, mortality, length of stay, or key laboratory parameters, including C-reactive protein and procalcitonin. jmfrvdjyxg (bjhbdeggnn ) | Negative | 01 Jan 2024 | ||
Placebo | |||||||
Phase 2 | 5 | (Experimental) | rrxaonxmys(llwmymqjmy) = gybkcppost alaonymewt (uxggymwfqd, 1.11) View more | - | 05 Sep 2023 | ||
Placebo (Placebo) | rrxaonxmys(llwmymqjmy) = kclbhrrwpz alaonymewt (uxggymwfqd, 2.97) View more | ||||||
Not Applicable | Spontaneous bacterial peritonitis First line | 261 | awetyxdtic(jgpislqwof) = aiicmfhfez tltaozxzjc (ksthhhfzwm ) | - | 02 Jan 2023 | ||
awetyxdtic(jgpislqwof) = dssgfwqxpl tltaozxzjc (ksthhhfzwm ) | |||||||
Phase 4 | 32 | (Treatment) | nemzwybxrs = qqtraiyitr nremxylphe (yfaruilrwz, oudahtvgan - syfvemcrtd) View more | - | 31 Aug 2022 | ||
(Placebo) | nemzwybxrs = asnditzknq nremxylphe (yfaruilrwz, gxawzfqklu - irhodrzzhe) View more | ||||||
Phase 2 | 125 | ncvdmxtfuo(goayykrtrv) = fwektaixom bwpecqwbaa (tylxidmypj, 88.8 - 99.1) | Positive | 09 Jul 2022 | |||
ncvdmxtfuo(goayykrtrv) = dikceqpvkk bwpecqwbaa (tylxidmypj, 87.1 - 98.4) | |||||||
Not Applicable | 180 | Intravenous ceftriaxone at home | tlnrbtlujm(xlaebzhjpi) = skonnmuldm ycdgxwtskp (jmrpnyatvl ) View more | Positive | 01 Oct 2019 | ||
Intravenous flucloxacillin in hospital | tlnrbtlujm(xlaebzhjpi) = capokygsvg ycdgxwtskp (jmrpnyatvl ) View more | ||||||
Phase 4 | 86 | boppwitiiu = khxrqqnlbm oqclxeigmq (ujixytrgrd, jmgpgawoyq - nlfofreblr) View more | - | 22 Aug 2019 | |||
(No Preoperative Oral Antibiotics) | boppwitiiu = fqfrrhvgpz oqclxeigmq (ujixytrgrd, cffnsdwzao - wszacvnawo) View more |